A2Add image
Ara-290
ImmuneSingleAlso known as: Cibinetide, ARA290
A non-erythropoietic erythropoietin analog studied for diabetic neuropathy, sarcoidosis-related small-fiber neuropathy, and tissue protection.
Half-life
2 h
Common dose
2 – 8 mg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
Ara-290 binds the innate repair receptor (a heteromer of EPOR and CD131), activating tissue-protective pathways without the erythropoietic (red-cell-raising) effects of EPO. Anti-inflammatory and neurotrophic effects have been described.
Protocol notes
Clinical trial protocols have used 2–8 mg subcutaneously daily for 4–28 days. Research dosing varies.
Reported side effects
Generally well-tolerated. Rare injection-site reactions.